Revolution Medicines (RVMD) Current Leases (2020 - 2026)
Revolution Medicines (RVMD) posted quarterly Current Leases of $16.6 million for Q1 2026, up 27.98% year-over-year from $13.0 million in Q1 2025, and up 0.86% quarter-over-quarter from $16.5 million in Q4 2025.
Revolution Medicines (RVMD) Current Leases (2020 - 2026) Analysis & Trends
Revolution Medicines' Current Leases history runs 7 years deep, the most recent figure standing at $16.6 million for Q1 2026.
- In Q1 2026, Current Leases rose 27.98% year-over-year to $16.6 million; the TTM figure through Mar 2026 stood at $16.6 million (up 27.98% YoY), while the FY2025 annual figure was $16.5 million, up 27.94% from the prior year.
- Current Leases for Q1 2026 stood at $16.6 million, up from $16.5 million in the prior quarter.
- The five-year high for Current Leases was $16.6 million in Q1 2026, with the low at $5.7 million in Q2 2023.
- The 5-year median for Current Leases is $8.2 million (2024), against an average of $9.7 million.
- The sharpest annual moves came in 2023 and 2025: Current Leases declined 17.98% in 2023, then surged 94.45% in 2025.
- Revolution Medicines' Current Leases stood at $6.8 million in 2022, then climbed by 8.8% to $7.4 million in 2023, then soared by 74.68% to $12.9 million in 2024, then climbed by 27.94% to $16.5 million in 2025, then advanced by 0.86% to $16.6 million in 2026.
- Business Quant data shows RVMD's Current Leases at $16.6 million in Q1 2026, $16.5 million in Q4 2025, and $16.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.75 Mn |
| Mar 31, 2026 | 16.61 Mn |
| Dec 31, 2025 | 16.47 Mn |
| Sep 30, 2025 | 16.33 Mn |
| Jun 30, 2025 | 13.09 Mn |
| Mar 31, 2025 | 12.98 Mn |
| Dec 31, 2024 | 12.87 Mn |
| Sep 30, 2024 | 8.40 Mn |
| Jun 30, 2024 | 8.33 Mn |
| Mar 31, 2024 | 8.17 Mn |
| Dec 31, 2023 | 7.37 Mn |
| Sep 30, 2023 | 5.76 Mn |
| Jun 30, 2023 | 5.72 Mn |
| Mar 31, 2023 | 5.92 Mn |
| Dec 31, 2022 | 6.77 Mn |
| Sep 30, 2022 | 7.02 Mn |
| Jun 30, 2022 | 6.03 Mn |
| Mar 31, 2022 | 6.33 Mn |
| Dec 31, 2021 | 6.21 Mn |
| Sep 30, 2021 | 4.96 Mn |